Development

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Articles

EFSA’s evaluation of risk in food products raises implications for drug product formulations. 

Considering Titanium Dioxide Regulatory Changes

Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.

Moderna and ILCM Announce Collaboration to Develop mRNA Therapeutic for CN-1

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Consistency, robustness, and understanding of the API and controlled-release excipients are essential for successful drug dosing.

On Time Delivery: Challenges of Controlled-Release Formulations

Editor of Pharmaceutical Technology Europe

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

Getting a Nose for Vaccines

Sunday Ndiana-Abasi is an intern pharmacist at the Department of Pharmaceutical Technology and Raw Materials Development in the National Institute for Pharmaceutical Research and Development in Nigeria.

Marlene Ekpo is a youth corp pharmacist and research assistant at the Centre for Nanomedicine and Biophysical Drug Delivery, National Institute for Pharmaceutical Research and Development, and a postgraduate student at the School of International Education, Southern Medical University, Guangzhou, Guangdong, China.

Martins O. Emeje, martinsemeje@yahoo.com, is a professor at the Department of Pharmaceutical Technology and Raw Materials Development and director of the Centre for Nanomedicine and Biophysical Drug Delivery, National Institute for Pharmaceutical Research and Development.

The potential for okra gum as a polymer candidate for new oral drug formulations was evaluated.

Evaluating Okra Gum in a Floating Tablet Formulation as a Novel Drug Delivery System

Deanna Mudie, PhD, is principal scientist, Lonza, Bend, OR, USA.

The pH effect encountered with oral oncology medication can be overcome with amorphous solid dispersions.

Enhanced Bioavailability of Acalabrutinib ASD Tablets In-Vivo

Dosage form priorities are shifting to focus on user-friendliness, leading to greater engagement with outsourcing partners earlier in development timelines.

Putting the Patient at the Heart of Dosage Form Design

Amorphous solid dispersions can overcome the pH effect encountered with oral oncology medications.

In-Vivo Demonstration of Enhanced Bioavailability of Acalabrutinib ASD Tablets

Collaborative partnerships can foster success in formulation development projects.

Developing the Best Formulation Partnership 

Recent research has highlighted the underlying mechanisms of amorphous solid dispersions and theory behind the formation of drug-rich phases.